After 100 years of use and billions of vaccinations, the world's deadliest infectious disease vaccine may soon be enhanced to meet the needs in 2025.
In a press release published on February 26, 2025, IAVI and Biofabri, a subsidiary of Zendal, announced that the first doses of tuberculosis MTBVAC vaccine candidate had been administered in the IMAGINE phase 2 clinical trial in Paarl, South Africa.
Read More
